CNTB Overview

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Wall Street analysts forecast CNTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTB is8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Connect Biopharma Holdings Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Connect Biopharma Holdings Ltd. EPS for the last quarter amounts to -0.27 USD, increased 68.75

Connect Biopharma Holdings Ltd (CNTB) has 64 emplpoyees as of April 21 2026.

Today CNTB has the market capitalization of 151.48M USD.